Literature DB >> 11328285

Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity.

R Ljung1, P Petrini, L Tengborn, E Sjörin.   

Abstract

The present series comprises all families (n = 77) with haemophilia B in Sweden and may be considered to be representative for the purposes of a population-based study of mutational heterogeneity. The 77 families (38 severe, 10 moderate, 29 mild) had 51 different mutations in total. Thirteen families had total, partial or small deletions, two had mutations in the promoter, eight families had splice site mutations, 14 had nonsense and the remaining 41 had missense mutations. Ten of the mutations, all C-->T or G-->A, recurred in 1--6 other families. Using haplotype analysis of seven polymorphisms in the factor IX (FIX) gene, we found that the 77 families carried 65 unique, independent mutations. Of the 48 families with severe or moderate haemophilia, 23 (48%) had a sporadic case of haemophilia compared with 31 families out of 78 (40%) in the whole series. Five of those 23 sporadic cases carried de novo mutations, 11 out of 23 of the mothers were proven carriers and, in the remaining seven families, it was not possible to determine carriership. Eleven of the 48 patients (23%) with severe haemophilia B developed inhibitors and all of them had deletions or nonsense mutations. Thus, 11 out of 37 (30%) patients with severe haemophilia B as a result of deletion/nonsense mutations developed inhibitors compared with 0 out of 11 patients with missense mutations. The ratio of male to female mutation rates was 5.3 and the overall mutation rate was 5.4 x 10(-6) per gamete per generation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328285     DOI: 10.1046/j.1365-2141.2001.02759.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Enhanced carrier and prenatal diagnosis in the Italian haemophilia B population.

Authors:  Anne Goodeve
Journal:  Blood Transfus       Date:  2007-07       Impact factor: 3.443

2.  Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors.

Authors:  Patrick Bonnet; Alessandro Gringeri; Edward Gomperts; Cindy Anne Leissinger; Roseline d'Oiron; Jerome Teitel; Guy Young; Meg Franklin; Bruce Ewenstein; Erik Berntorp
Journal:  Am Health Drug Benefits       Date:  2011-07

Review 3.  Proteases as therapeutics.

Authors:  Charles S Craik; Michael J Page; Edwin L Madison
Journal:  Biochem J       Date:  2011-04-01       Impact factor: 3.857

4.  Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B.

Authors:  Claudia Pamela Radic; Liliana Carmen Rossetti; Miguel Martín Abelleyro; Miguel Candela; Raúl Pérez Bianco; Miguel de Tezanos Pinto; Irene Beatriz Larripa; Anne Goodeve; Carlos Daniel De Brasi
Journal:  Thromb Haemost       Date:  2012-10-23       Impact factor: 5.249

5.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

Authors:  Federico Mingozzi; Yi-Lin Liu; Eric Dobrzynski; Antje Kaufhold; Jian Hua Liu; YuQin Wang; Valder R Arruda; Katherine A High; Roland W Herzog
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

6.  A Line 1 insertion in the Factor IX gene segregates with mild hemophilia B in dogs.

Authors:  Marjory B Brooks; Weikuan Gu; Jennifer L Barnas; Jharna Ray; Kunal Ray
Journal:  Mamm Genome       Date:  2003-11       Impact factor: 2.957

7.  Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model.

Authors:  Valder R Arruda; Hansell H Stedman; Timothy C Nichols; Mark E Haskins; Matthew Nicholson; Roland W Herzog; Linda B Couto; Katherine A High
Journal:  Blood       Date:  2004-10-12       Impact factor: 22.113

8.  Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX.

Authors:  Ou Cao; Elina Armstrong; Alexander Schlachterman; Lixin Wang; David K Okita; Bianca Conti-Fine; Katherine A High; Roland W Herzog
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

Review 9.  Homing endonucleases: from basics to therapeutic applications.

Authors:  Maria J Marcaida; Inés G Muñoz; Francisco J Blanco; Jesús Prieto; Guillermo Montoya
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

Review 10.  Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B.

Authors:  Claudia Djambas Khayat
Journal:  J Blood Med       Date:  2016-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.